PDCD1 and breast cancer: Therefore, it is hypothesized that inhibition of angiogenesis may sensitize tumors to immunotherapy, and addition of antiangiogenic agents to programmed cell death-1 (PD-1) inhibitors could result in an improved antitumor response in breast cancer [11, 12].